Journal of Managed Care & Specialty Pharmacy

Article	Citations
Correction	125
Incremental health care expenditures for non-Hodgkin lymphoma in comparison with other cancers: Analysis of national survey data	47
Specialty drug use for autoimmune conditions varies by race and wage among employees with employer-sponsored health insurance	25
The effectiveness and value of midomafetamine-assisted psychotherapy for posttraumatic stress disorder	22
Medicare drug price negotiation: The complexities of selecting therapeutic alternatives for estimating comparative effectiveness	22
Pediatric-onset rare disease therapy pipeline yields hope for some and gaps for many: 10-year projection of approvals, treated patients, and list price revenues	20
PIVOT: Pharmacist Interventions for Value and Outcome Transformation in Specialty Pharmacy	19
Compliance with the Veterans Health Administration’s Pharmacy Benefit Management guidance for duration of clopidogrel following peripheral vascular interventions: a retrospective cohort study	18
Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies	15
Real-world calibration and transportability of the Disease Recovery Evaluation and Modification (DREaM) randomized clinical trial in adult Medicaid beneficiaries with recent-onset schizophrenia	15
Associations between chronic active lesions and clinical outcomes in multiple sclerosis: A systematic literature review	15
Evaluating the feasibility of health care databases for assessing the safety of switching between originator biologics and biosimilars	14
The effect of early initiation of aripiprazole once-monthly 400 mg on health care resource utilization and health care costs in patients diagnosed with bipolar I disorder: Real-world evidence from US	14
Emerging trends in therapeutics and diagnostics: Perspectives on the 2024 AMCP Foundation Survey	14
Cost avoidance from health system specialty pharmacist interventions in patients with multiple sclerosis	14
Real-world evidence: A new era is upon us	14
Principles and practices for successful gene therapy innovative contracting: Insights from a multistakeholder convening	14
Poster Abstracts - Academy of Managed Care Pharmacy 2024	13
Navigating the landscape of food allergies: Insights and perspectives from the AMCP Market Insights Program	13
Patient factors and costs associated with prophylactic neurokinin-1 receptor antagonist use among women with invasive breast cancer	13
Iptacopan and danicopan for paroxysmal nocturnal hemoglobinuria	12
Assessing health care resource use, outcomes, and costs among Medicaid beneficiaries receiving factor IX prophylaxis for hemophilia B	11
Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol	11
Pharmacist impact on evidence-based prescribing of diabetes medications in patients with clinical atherosclerotic cardiovascular disease	11
Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with schizophrenia in the United States	11

Real-world costs, treatment patterns, and clinical outcomes associated with treatments for advanced anaplastic lymphoma kinase–positive non–small cell lung cancer	11
AMCP Market Insights: Beyond skin deep on the role of managed care in moderate to severe atopic dermatitis	11
Real-world primary nonadherence to antiobesity medications	11
Impact of telehealth on hydroxyurea adherence and clinical outcomes in sickle cell disease management: A systematic review and meta-analysis	10
Evaluating patient-reported adherence and outcomes in specialty disease states: A dual-site initiative	10
Introducing the Managed Care Pharmacy Primer Series	10
Evaluating the burden of illness of metabolic dysfunction–associated steatohepatitis in a large managed care population: The ETHEREAL Study	10
Considerations for US coverage and reimbursement: Which digital health products to evaluate? Findings from a modified Delphi study	10
Copay assistance use and prescription abandonment across race, ethnicity, or household income levels for select rheumatoid arthritis and oral oncolytic medicines	9
Differences in GLP-1 RA medication adherence across place-based variables in patients with diabetes living in Wisconsin	9
Emerging trends in pharmaceutical payment models: Perspectives on the 2024 AMCP Foundation Survey	9
Underutilization or appropriate care? Assessing adjuvant chemotherapy use and survival in 3 heterogenous subpopulations with stage II/III colorectal cancer within a large integrated health system	9
Impact of a pharmacist-led hepatitis C clinic on hepatitis A and B vaccination rates and treatment outcomes: A retrospective cohort study	9
Assessing the impact of a financial incentive and refill reminder program on medication adherence and costs	9
Evolution of the Military Health System compounded drugs utilization and management	9
Place of care and costs associated with acute episodes and remission in schizophrenia	9
Poster Abstracts - Academy of Managed Care Pharmacy 2026	9
AMCP Format for Formulary Submissions 5.0	9
First-line cyclin-dependent kinase 4 and 6 inhibitors in combination with an aromatase inhibitor for HR+/HER2- metastatic breast cancer: A real-world cost-effectiveness assessment in a US Medicare-eli	8
Correction	8
The association of direct-acting antiviral therapy with health care utilization and costs in patients with chronic hepatitis C virus infection: A systematic review of real-world studies in the United	8
Employee retention for subscribers with and without an obesity diagnosis in self-insured employer health plans: A claims-based analysis	8
Cost sharing in managed care and the ethical question of business purpose	8
Nationwide trends in hospitalization, medical costs, and mortality for asthma after introduction of biologics: A cross-sectional study in the United States	8
Impact of next-generation sequencing vs polymerase chain reaction testing on payer costs and clinical outcomes throughout the treatment journeys of patients with metastatic non–small cell lung cancer	8
Addressing gaps to strengthen patient-centricity in formulary decision-making: An example applied to Colorado’s prescription drug affordability board implementation	8
Trends in opioid prescribing by oncologists for Medicare beneficiaries from 2014 to 2022	8
Burden of chronic corticosteroid use among patients with ulcerative colitis initiated on targeted treatment or conventional therapy in the United States	8
Emerging trends in pharmaceutical payment models: Perspectives on the 2024 AMCP Foundation Survey	8
Economic burden related to fistulas or strictures among commercially insured patients with Crohn’s disease in the United States	8
Trends in delivery of comprehensive medication reviews by race and ethnicity, 2013-2021	8
Antidepressant adherence using group-based trajectory modeling among postpartum women with Texas Medicaid	8
Health care costs among patients with relapsed/refractory multiple myeloma treated with ixazomib or daratumumab in combination with lenalidomide and dexamethasone in the United States	8
Using a patient-centered value assessment to optimize fair prices for Inflation Reduction Act’s Medicare Drug Price Negotiation Program	8
Trends in use of continuous glucose monitors among individuals with type 2 diabetes enrolled in Medicare Advantage (2021–2023)	7
Nonfederal average manufacturer price to estimate savings generated by minimum discounts under the Inflation Reduction Act	7
Correction	7
Bundling medical and pharmacy benefits: Impact on medical costs	7
A dynamic analysis of medication adherence	7
Infusion therapy patient outcomes are similar at reduced costs in alternative sites of care compared with hospital outpatient departments: A matched cohort analysis of infusion therapy across multiple	7
Impact of mental health in persons living with rare disease: Findings from the AMCP Market Insights Program	7
Patient-reported disability progression outcomes among patients with multiple sclerosis: Results of an outcomes-based agreement	7
Imetelstat for anemia in lower-risk myelodysplastic syndromes: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum	7
Resmetirom for nonalcoholic steatohepatitis	7
Polypharmacy in US Medicare beneficiaries with antineutrophil cytoplasmic antibody vasculitis	7
Poster Abstracts - Academy of Managed Care Pharmacy 2025	7
Use of clinical outcome assessments in specialty drug coverage policies	7
Aligning payer and provider strategies with the latest evidence to optimize clinical outcomes for patients with neuromyelitis optica spectrum disorder	7
AMCP Market Insights: Payer best practices in food allergy management	7
Characterizing Medicare Medication Therapy Management program enrollees with central nervous system–active polypharmacy	7

Equivalent effectiveness of a prescription binocular treatment for amblyopia in real-world practice	7
The use of short-acting bronchodilators and cost burden of asthma across Global Initiative for Asthma–based severity levels: Insights from a large US commercial and managed Medicaid population	7
Burden of illness and unmet needs in patients with erythropoietic protoporphyria and X-linked protoporphyria: A large US nationwide claims analysis	7
AMCP Market Insights: Impact of the evolving understanding of multiple sclerosis and emerging treatment approaches on managed care	6
Socioeconomic, demographic, and medication class determinants of medication adherence: A retrospective cohort study	6
Persistence and other treatment patterns among bio-experienced patients with Crohn’s disease initiated on ustekinumab or adalimumab	6
Health care resource utilization and costs in patients with painful diabetic neuropathy treated with 10 kHz spinal cord stimulation therapy	6
The impact of a statewide insulin copay cap policy for insured patients with diabetes in Utah	6
Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: A novel topical therapy targeting the aryl hydrocarbon receptor	6
Financial impact of integrated specialty pharmacy efforts to avoid oral anticancer medication waste	6
Cost per outcome of nivolumab + relatlimab vs BRAF + MEK inhibitor combinations for first-line treatment of BRAF-mutant advanced melanoma	6
Insights into insurance coverage for digital therapeutics: A qualitative study of US payer perspectives	6
Impact of CDK4/6 inhibitors on health-related quality of life outcomes in patients with metastatic breast cancer: A systematic review and meta-analysis	6
Descriptive, real-world treatment patterns, resource use, and total cost of care among eculizumab- and ravulizumab-treated members with paroxysmal nocturnal hemoglobinuria	6
Effect of the population health inpatient Medicare Advantage pharmacist intervention on hospital readmissions: A quasi-experimental controlled study	6
Real-time continuous glucose monitoring related to reductions in inpatient and emergency department encounters and their associated costs among non–insulin-treated people with type 2 diabetes	6
Real-world switching and discontinuation outcomes of infliximab biosimilars in patients with rheumatoid arthritis: A scoping review	6
The landscape of real-world evidence of rituximab utilization and clinical outcomes in patients with cancer, rheumatoid arthritis, and multiple sclerosis: A scoping review	6
Beyond glycemic control: Sex differences shaping glucagon-like peptide-1 receptor agonist utilization in the United States	6
Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States	6
Health care costs and resource utilization among patients with myasthenia gravis in the United States	6
Emerging trends in public policy: Perspectives on the 2024 AMCP Foundation Survey	6
Building health plan–pharmacist provider partnerships to optimize medication outcomes	6
Health care resource utilization and costs among patients with spasticity or cervical dystonia	6
Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: Effectiveness and value	6
Correction Statement	6
Treatment patterns, health care resource utilization, and costs of heavily treatment-experienced people with HIV in the United States	6
Real-world outcomes and direct care cost before and after elexacaftor/tezacaftor/ivacaftor initiation in commercially insured members with cystic fibrosis	6
Advancing the conversation: 30 years of scholarship in managed care pharmacy	5
Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective	5
Prevalence, adherence, and health care resource utilization in schizophrenia: A national and state-level analysis of US Medicaid Beneficiaries	5
Descriptive study of the economic burden among patients with type 2 diabetes mellitus, chronic kidney disease, and chronic kidney disease and type 2 diabetes mellitus in a large US commercially insure	5
Budget impact of xanomeline and trospium chloride for the treatment of adults with schizophrenia in the United States	5
Prompt initiation of triple therapy following hospitalization for a chronic obstructive pulmonary disease exacerbation in the United States: An analysis of the PRIMUS study	5
Real-world treatment patterns, resource use, and costs in human epidermal growth factor receptor 2–negative advanced gastric/gastroesophageal junction cancer in the United States in the immune checkpo	5
Impact of copay maximizers on total patient liability among patients using specialty medicines	5
Will the emerging private-label market access channel help or hinder biosimilar market access?	5
Associations between pharmacy choice and influenza vaccination: Mail order vs community pharmacy users	5
Examining US commercial health plans’ use of The Institute for Clinical and Economic Review’s reports in specialty drug coverage decisions	5
Atidarsagene autotemcel for metachromatic leukodystrophy	5
Oral treatments for outpatient COVID-19: Effectiveness and value	5
A cost comparison of benralizumab, mepolizumab, and dupilumab in patients with severe asthma: A US third-party payer perspective	5
The effectiveness and value of suzetrigine for moderate to severe acute pain: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council	5
Comparison of a second TNFi vs other biologic or targeted synthetic DMARD following an initial TNFi	5
Predictors of flare-related inpatient or emergency department stay in systemic lupus erythematosus: A real-world analysis of Medicaid claims in the United States	5
A primer on copay accumulators, copay maximizers, and alternative funding programs	5
Associations of oseltamivir with neuropsychiatric and behavioral adverse events: A systematic review and meta-analysis	5
Herpes zoster vaccine uptake following provider prescription among older adults in the United States	5
Patient liability, treatment adherence, and treatment persistence associated with state bans of copay accumulator adjustment programs	5
Limited utility of price transparency data for drugs	5
Pharmacists as clinical care partners: How a pharmacist-led intervention is associated with improved medication adherence in older adults with common chronic conditions	5
Pharmacoequity measurement framework: A tool to reduce health disparities	5
AMCP Market Insights: Payer best practices for timely diagnosis and optimal management of idiopathic hypersomnia	5
Utilization and patient characteristics for the trastuzumab reference and biosimilars, and other human epidermal growth factor receptor 2 inhibitors in the United States	5
Characterizing health plan evidence review practices	5
A comparison of clinical, utilization, and cost outcomes between oral treatments for multiple sclerosis	5
Cost-effectiveness analysis of treatment strategies initiating with second-generation antipsychotic long-acting injectables in patients with schizophrenia in the United States	5
Treatment patterns and hospitalizations following rejection, reversal, or payment of the initial once-monthly paliperidone palmitate long-acting injectable antipsychotic claim among patients with schi	5
Sustaining competition for biosimilars on the pharmacy benefit: Use it or lose it	5
Dynamic changes in medication burden leading to fall and hospital readmissions in older adults: Toward a strategy for improving risk and managing costs	4
Does the diabetes health plan have a differential impact on medication adherence among beneficiaries with fewer financial resources?	4
Cost-related barriers to medication use among diverse participants with obesity-associated asthma	4
The time is now: Addressing health inequities in the workforce	4
Shared visits vs incident-to billing for pharmacy services	4
Marginal health care expenditures for melanoma care in the United States	4
Patterns and costs associated with glucagon-like peptide-1 receptor agonist use in US adults with type 2 diabetes	4
Thanks to JMCP Peer Reviewers, 2025	4
Improving adherence to guideline-based lipid-lowering therapy in people with hyperlipidemia using a targeted educational outreach approach	4
Optimizing maintenance dosing of emicizumab-kxwh as prophylaxis in hemophilia A: Dosing to product labeling while minimizing drug waste	4
Treatment patterns, health care resource utilization and costs, and clinical outcomes among older adult patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma	4
Pathways for innovation—Expansion of health system specialty pharmacy services: A pilot initiative in dermatology and rheumatology clinics	4
Impact of a pharmacy care management service on cardiometabolic medication adherence and resource use for Medicare Advantage beneficiaries	4
Correction	4
Health care resource utilization and costs associated with psychiatric comorbidities in adult patients with attention-deficit/hyperactivity disorder	4
Addressing complexity: The development and pilot testing of a user-friendly Medicare Part D patient decision aid tool	4
Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with bipolar I disorder in the United States	4
Poster Abstracts - Academy of Managed Care Pharmacy 2022	4
Real-world utilization of top-down and step-up therapy and initial costs in Crohn disease	4
The effectiveness and value of sonpiretigene isteparvovec for the treatment of advanced retinitis pigmentosa	4
Inhaled treprostinil vs iloprost: Comparison of adherence, persistence, and health care resource utilization in patients with pulmonary arterial hypertension	4

HIV preexposure prophylaxis treatment patterns in a national health plan population	4
An online survey among US patients with immune-mediated conditions: Attitudes about biosimilars	4
Dose escalation of biologics in biologic-naive patients with Crohn’s disease: Outcomes from the ODESSA-CD study	4
Effect of the initial combination approach vs initial monotherapy approach on 1-year trajectories of adherence in drug-naive patients with type 2 diabetes	4
Primary care physicians prescribe fewer expensive combination medications than dermatologists for acne: A retrospective review	4
Predicting pharmacy choice for managed care network design	4
Unlocking the potential of digital therapeutics: The need for consistent and granular inclusion in drug compendia for managed care	4
Clinical and economic characterization of mild, moderate, and severe systemic lupus erythematosus: Real-world observation across payer channels in the United States	4
Drugs anticipated to be selected for Medicare price negotiation in 2026 for implementation in 2028	4
Descriptive study of the real-world, long-term cost estimates and duration of use for hormonal and nonhormonal intrauterine devices using US commercial insurance claims	4
Pharmacist vs physician management of e-visit requests for COVID-19 medication: A randomized clinical trial	4
Emerging trends in pharmacy operations: Perspectives on the 2024 AMCP Foundation Survey	4
Finding consensus on meaningful reporting measures for rheumatoid arthritis: Results from a modified Delphi study	4
Marginal health care expenditures and health-related quality of life burden in patients with migraine	4
Impact of social determinants of health on esketamine nasal spray initiation among patients with treatment-resistant depression in the United States	4
Evolving oncology care management trends in the United States: A survey among health care decision makers	4
Cost-effectiveness of early vs delayed use of abemaciclib combination therapy for patients with high-risk hormone receptor–positive/human epidermal growth factor receptor 2–negative early breast cance	4
Health care utilization and costs associated with acute exacerbation of fibrosing interstitial lung disease in the United States: A retrospective administrative claims database analysis	4
Assessing variation in US payer coverage of anti–vascular endothelial growth factor therapies for the treatment of age-related macular degeneration, diabetic retinopathy, and diabetic macular edema	4
Correction	3
Best practices and rationale for expanding Medicaid access to continuous glucose monitoring	3
Real-world health care costs and resource utilization associated with mild cognitive impairment in the United States: A retrospective cohort study of commercial and Medicare data	3
Identifying potentially undiagnosed nontuberculous mycobacterial lung disease among patients with chronic obstructive pulmonary disease: Development of a predictive algorithm using claims data	3
Impact of pharmacist alternative therapy interventions in a pediatric Medicaid population	3
Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: A novel topical therapy targeting the aryl hydrocarbon receptor	3
Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy	3
Transparent reporting of group-based trajectory modeling to study medication adherence: Practical considerations and common pitfalls	3
Changes in blood pressure, medication adherence, and cardiovascular-related health care use associated with the 2018 angiotensin receptor blocker recalls and drug shortages among patients with hyperte	3
Using continuous glucose monitoring to measure and improve quality metrics: Updates on the Healthcare Effectiveness Data and Information Set 2024 Glucose Management Indicator measure	3
Telephone-based social health screening by pharmacists in the nonadherent Medicare population	3
Continuous glucose monitoring for self-management of diabetes in people living with type 2 diabetes mellitus on basal insulin therapy: A microsimulation model and cost-effectiveness analysis from a US	3
Development of stakeholder-informed recommendations for inclusion of family spillover effects in health technology assessment	3
Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence study	3
Area deprivation index impact on type 2 diabetes outcomes in a regional health plan	3
Addressing racial inequality and its effects on vaccination rate: A trial comparing a pharmacist and peer educational program (MOTIVATE) in diverse older adults	3
Association of health care utilization and costs with patient-reported outcomes in patients with ankylosing spondylitis	3
Impact of formulary-related pharmacy claim rejections of cariprazine on health care utilization and treatment patterns among patients with bipolar I disorder	3
Patient experience data in formulary decision-making: Payer-reported perceptions and use	3
Geographic atrophy: Mechanism of disease, pathophysiology, and role of the complement system	3
Identifying therapeutic alternatives in Medicare drug price negotiation: The case of etanercept	3
Real-time continuous glucose monitoring vs self-monitoring of blood glucose in distinct multi-ethnic cohorts of patients living with insulin-treated type 2 diabetes in the United States: A cost-utilit	3
Real-world effectiveness of omadacycline and impact of unapproved omadacycline prescription claims among adult outpatients with community-acquired bacterial pneumonia or acute bacterial skin and skin	3
Within-trial economic analysis of resource use from COMET-ICE: A phase 3 clinical trial evaluating sotrovimab for the treatment of patients with COVID-19 at high risk of progression	3
The Washington State Prescription Drug Affordability Board’s selection of drugs for affordability review	3
Health care resource utilization and costs associated with atrial fibrillation and rural-urban disparities	3
Burden of lipoprotein(a) for patients with atherosclerotic cardiovascular disease: A retrospective analysis from the United States	3
Perceptions of prior authorization by use of electronic prior authorization software: A survey of providers in the United States	3
Real-world use of semaglutide for obesity treatment: A cohort study in an integrated health care delivery system	3
Cost-effectiveness of direct-acting antivirals for chronic hepatitis C virus in the United States from a payer perspective	3
Comorbidities and neighborhood factors associated with prescription of sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists among medically underserved popul	3
Optimizing the management of inherited blood disorders in a changing market: Findings from the AMCP Market Insights Program	3
Emerging trends in managed care pharmacy: A mixed-method study	3
Real-world treatment utilization and economic implications of lupus nephritis disease activity in the United States	3
Specialty pharmacy turnaround time impediments, facilitators, and good practices	3
Implementation of a nonstatin prior authorization checklist for patients with hypercholesterolemia: In 2 community health care systems	3
Impact of a real-time prescription benefit on adherence and utilization of low-cost prescription alternatives for members new to diabetes treatment	3
A primer on clinical programs in managed care pharmacy	3
Antiretroviral therapy switch among Medicare beneficiaries with HIV	3
Health care resource utilization and costs in patients receiving long-acting injectable vs oral antipsychotics: A comparative analysis from the Disease Recovery Evaluation and Modification (DREaM) stu	3
Impact of discontinuing disease-modifying therapies on health care utilization among midlife patients with multiple sclerosis in the United States	3
Understanding patient cost-sharing thresholds for diabetes treatment attributes via a discrete choice experiment	3
A summit on amplifying voices of patients, caregivers, and people with disabilities in Inflation Reduction Act drug price negotiations	3
Individual and social determinants of adherence to sodium-glucose cotransporter 2 inhibitor therapy: A trajectory analysis	3
Burden of illness in progressive fibrosing interstitial lung disease	3
Determining health care cost drivers in older Hodgkin lymphoma survivors using interpretable machine learning methods	3
Manufacturer-sponsored drug coupon use and drug-switching behavior among patients with type 2 diabetes	3
Real-world adherence to and persistence with emicizumab in people with hemophilia A using a national claims database	3
Unmanaged depression and chronic disease medication adherence in Medicare Advantage beneficiaries: A claims-based analysis	3
Real-world adherence, persistence, and health care resource utilization among people with HIV receiving long-acting cabotegravir plus rilpivirine compared with oral antiretroviral therapy in the Unite	3
The impact of opioid prescribing report cards in Medicaid	3
Comorbid depression and anxiety and their association with health care resource utilization among individuals with type 1 diabetes in the United States	3
Risk of chemotherapy-induced febrile neutropenia in intermediate-risk regimens: Clinical and economic outcomes of granulocyte colony-stimulating factor prophylaxis	3
A systematic review of cost-effectiveness analyses of gene therapy for hemophilia type A and B	3
Real-world 6-month persistence, adherence, and effectiveness of GLP-1 medications for overweight and obesity in a Medicaid population	3
Impact of a human papillomavirus vaccination clinical program in a commercially insured population	3
Impact of pharmacist-physician collaborative care on hemoglobin A1c and blood pressure quality measure achievement in primary care	3
AMCP Market Insights: Navigating the rapidly changing landscape of ER+/HER2− metastatic breast cancer	3
Risk of herpes zoster among adults in the United States initiating immunosuppressive therapy: A retrospective cohort study	3
Predictors of adherence to direct oral anticoagulants after cardiovascular or bleeding events in Medicare Advantage Plan enrollees with atrial fibrillation	3
Estimating the excess expenditures associated with glucagon-like peptide-1 receptor agonist use among adults with diabetes in the United States	3
Health care resource utilization and costs among individuals with vs without Huntington disease in a US population	3
Reasons for switching oral antipsychotic medications and related patterns of care and costs in patients with schizophrenia initiating monotherapy treatment: Claims-linked chart study	3
Concentration of spending and share of specialty drug spending in Medicare Part D over a 10-year period	3
Poster Abstracts - NEXUS 2025	3
Trends in first-line glucose-lowering medication use among US adults with type 2 diabetes from 2019 to 2023	2
Primary medication nonadherence rates to specialty disease-modifying antirheumatic drugs for rheumatoid arthritis within a health system specialty pharmacy	2
Adherence, health care utilization, and costs between long-acting injectable and oral antipsychotic medications in South Carolina Medicaid beneficiaries with schizophrenia	2
The burden of heart failure in the United States: Medical costs and health-related quality of life	2
Poster Abstracts - Academy of Managed Care Pharmacy 2024	2
Predictors of adherence to oral anticancer medications: An analysis of 2010-2018 US nationwide claims	2
KarXT for schizophrenia–effectiveness and value: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council	2
Price benchmarks of drugs selected for Medicare price negotiation and their therapeutic alternatives	2
Implications of treatment duration and frequency for value and cost-effective price of Alzheimer treatments	2
Emerging trends in managed care pharmacy: A mixed-method study	2
It is time for a more nuanced discussion about pharmacy benefit managers	2